Vitreous Mediators after Intravitreal Bevacizumab or Triamcinolone Acetonide in Eyes with Proliferative Diabetic Retinopathy
Vitreous Mediators after Intravitreal Bevacizumab or Triamcinolone Acetonide in Eyes with Proliferative Diabetic Retinopathy
复制标题
DOI：
10.1016/j.ophtha.2008.12.024
复制
发表时间：
2009-05-01
期刊：
影响因子：
13.7
通讯作者：
Sakamoto, Taiji
中科院分区：
文献类型：
--
作者：
Arimura, Noboru;Otsuka, Hiroki;Sakamoto, Taiji
目的：评价玻璃体血管内皮生长因子（VEGF）、基质细胞衍生因子1 α（SDF 1 α）（SDF-1 α）、白细胞介素（IL）和肿瘤坏死因子-α（TNF-alpha）在患有增殖性糖尿病视网膜病变（PDR）的眼睛中玻璃体内注射贝伐单抗或曲安奈德（TA）后的变化。设计：具有历史对照的干预性、连续性、回顾性、比较性研究。研究了47例活动性PDR患者的47只眼。贝伐单抗组19眼玻璃体腔注射贝伐单抗1.25 mg，TA组10眼玻璃体腔注射TA 4 mg。18只未注射眼作为对照方法：在玻璃体切除术中获得玻璃体样本并分析总蛋白、VEGF、SDF-1 α、IL-1 β、IL-6、IL-8、IL-10、IL-12 p70和TNF-α的浓度。比较贝伐单抗、TA和对照组之间VEGF、SDF-1 α、IL和TNF-α的维生素浓度。与对照组相比，贝伐单抗和TA组中VEGF和SDF-1 α的维生素浓度较低。贝伐珠单抗组的中位VEGF水平为0 pg/ml（范围：0-79.2 pg/ml），TA组为343.5 pg/ml（范围：0-1683.3 pg/ml），对照组为1202.5 pg/ml（范围：76-4213.9 pg/ ml）。贝伐珠单抗组的中位SDF-1 α水平为149.2 pg/ ml（范围：0-519.4 pg/ ml），TA组为87.5 pg/ ml（范围：0-252.5 pg/ ml），对照组为245.7 pg/ ml（范围：0-856.8 pg/ ml）。玻璃体VEGF和SDF-1 α浓度在3组间差异均有统计学意义（P
Purpose: To evaluate vitreous vascular endothelial growth factor (VEGF), stromal cell-derived factor 1 alpha (SDF-1 alpha), interleukins (ILs), and tumor necrosis factor-alpha (TNF-alpha) after intravitreal bevacizumab or triamcinolone acetonide (TA) in eyes with proliferative diabetic retinopathy (PDR).Design: Interventional, consecutive, retrospective, comparative study with a historical control.Participants: Forty-seven eyes of 47 patients affected by active PDR were investigated. Bevacizumab (1.25 mg; 19 eyes; bevacizumab group) or TA (4 mg; 10 eyes; TA group) was injected into the vitreous cavity as preoperative adjunctive therapy 7 days before vitrectomy. Eighteen eyes without injection served as controls (control group).Methods: The vitreous samples were obtained at vitrectomy and were analyzed for concentrations of total protein, VEGF, SDF-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, IL-12p70, and TNF-alpha.Main Outcome Measures: Vitreous concentrations of VEGF, SDF-1 alpha, ILs, and TNF-alpha were compared among bevacizumab, TA, and control groups.Results: Vitreous concentrations of VEGF and SDF-1 alpha were lower in bevacizumab and TA groups compared with the control group. The median VEGF level was 0 pg/ml (range, 0-79.2 pg/ml) in the bevacizumab group, 343.5 pg/ml (range, 0-1683.3 pg/ml) in the TA group, and 1202.5 pg/ml (range, 76-4213.9 pg/ ml) in the control group. The median SDF-1 alpha level was 149.2 pg/ ml (range, 0-519.4 pg/ ml) in the bevacizumab group, 87.5 pg/ ml (range, 0-252.5 pg/ ml) in the TA group, and 245.7 pg/ ml (range, 0-856.8 pg/ ml) in the control group. The differences in both vitreous VEGF and SDF-1 alpha concentrations among 3 groups were statistically significant (P